NeuroThera Labs Granted Japanese Patent for its Proprietary, Innovative Therapeutic Combination

Toronto, Ontario – TheNewswire - A ugust 12 , 2026 – NeuroThera Labs Inc. (TSXV: NTLX) (the " Company " or " NeuroThera "), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), today announced that the Japanese Patent Office has granted the company a patent for its pharmacological combination titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” The newly granted Japanese patent covers pharmaceutical compositions and methods comprising proprietary combinations of 4-aminophenols derivatives (including paracetamol) and N-acylethanolamines. These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies. NeuroThera believes this synergistic approach may enable lower effective dosing while helping to mitigate dose ‑ related side ‑ effect concerns associated with established treatments. This patent further strengthens NeuroThera’s expanding intellectual property portfolio reinforcing protection for its combination-therapy platforms designed to optimize and modernize standard treatments for pain, fever, and related conditions. The addition of Japanese patent cove

Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes